企業プロフィール

Incyte 株価・ニュース・カタリスト

ティッカー:
INCY
取引所:
NASDAQ
セクター:
Biopharma
所在地:
Wilmington, Delaware

株価パフォーマンス

123.50 USD (+2.78%)

終値

最終更新: 2026年8月17日

18.4B USD

時価総額

株価変動の要因

As of Aug 17, 2026, INCY closed up 2.78% at $123.50. No new same-company headline was identified in the current news window.

企業概要

事業概要

Incyte is a biopharmaceutical company focused on hematology, oncology, and inflammation. Its business combines a commercial base with a pipeline that continues to produce new opportunities in immunology and cancer.

所在地とセクター分類

Headquartered in Wilmington, Delaware and listed on NASDAQ, Incyte is a U.S.-based biotech with meaningful global commercial and development exposure. It sits in specialty biopharma rather than general healthcare.

ビジネスモデルの特徴

The company generates value through marketed products, R&D, and pipeline expansion across oncology and inflammatory disease. Investors track revenue durability, new data, and whether the next wave of programs can keep replacing mature growth.

バイオ業界での位置付け

Incyte is a well-established biotech name with enough commercial scale to soften pure binary risk, but it still reacts to clinical data and label expansion. It sits in a strong middle ground between mature pharma and high-volatility development biotech.

今後のカタリスト

  • Incyte’s near-term catalysts are Opzelura growth, povorcitinib readouts, and any label-expansion or pipeline update in dermatology and oncology. That readout matters because it decides whether the asset is ready for a larger and more expensive development step. If the data come in cleanly, the market tends to give the broader platform behind the program more credit.

最近のニュース

    類似銘柄

    事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。